Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапии тела. Часть ІІІ. Рак предстательной железы
Автор: Паньшин Г.А.
Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr
Рубрика: Обзор
Статья в выпуске: 1 т.24, 2024 года.
Бесплатный доступ
Данная статья является продолжением начального цикла статей, посвященных современному состоянию вопроса о роли дистанционной стереотаксической абляционной радиотерапии тела (ДСАРТТ) при олигометастатической болезни (ОМБ). В первом сигнальном сообщении по данной проблеме (Вестник РНЦРР. 2023. Т. 23, №3) были освещены общие вопросы, связанные с применением ДСАРТТ у больных с ОМБ. В последующих публикациях уже было оценено современное состояние вопроса о реализации ДСАРТТ при ОМБ рака легкого и молочной железы. Для того, чтобы не было какой-либо двусмысленности при определении ОМБ при раке предстательной железы (РПЖ), которое может возникать, как при гормонально-чувствительных опухолях, так и в клинической практике у больных с кастрационно-резистентным РПЖ, в данной статье рассматриваются вопросы, связанные только с олигометастатическим гормоночувствительным РПЖ, а именно: биология, доказательства и противоречия, касающиеся синхронного ДСАРТТ de novo олигометастатического гормоночувствительного РПЖ.
Синхронный олигометастатический гормоночувствительный рак простатыde novo, дистанционная стереотаксическая абляционная радиотерапия тела
Короткий адрес: https://sciup.org/149145021
IDR: 149145021
Список литературы Олигометастатическая болезнь и дистанционная стереотаксическая абляционная радиотерапии тела. Часть ІІІ. Рак предстательной железы
- Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 Jan;77(1):38-52. doi: 10.1016/j.eururo.2019.08.005.
- Prostate - Global Cancer Observatory. Доступно по адресу: https://gco.iarc.fr/today/data/factsheets/cancers/27-Prostate-fact-sheet.pdf. Дата обращения: 07.08.2023.
- Helgstrand JT, Røder MA, Klemann N, Toft BG, Lichtensztajn DY, Brooks JD, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-Apopulation-based analysis of 2 national cohorts. Cancer. 2018 Jul 15;124(14):2931-2938. doi: 10.1002/cncr.31384.
- Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, et al. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042.
- Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 Dec;19(4):395-397. doi: 10.1038/pcan.2016.30.
- Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, Sedrakyan A. Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. JAMA Oncol. 2017 May 1;3(5):705-707. doi: 10.1001/jamaoncol.2016.5465. Erratum in: JAMA Oncol. 2017 May 1;3(5):709.
- Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020 Apr;77(4):403-417. doi: 10.1016/j.eururo.2019.01.049.
- Piombino C, Oltrecolli M, Tonni E, Pirola M, Matranga R, Baldessari C, et al. de novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment? Cancers (Basel). 2023 Oct 11;15(20):4945. doi: 10.3390/cancers15204945.
- Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-746. doi: 10.1056/NEJMoa1503747.
- James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al; STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19;387(10024):1163-1177. doi: 10.1016/S0140-6736(15)01037-5.
- Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174.
- James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al; STAMPEDE Investigators. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900.
- Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835.
- Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, et al. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021 May;205(5):1361-1371. doi: 10.1097/JU.0000000000001568.
- Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, et al; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307.
- Szturz P, Vermorken JB. Oligometastatic Cancer: Key Concepts and Research Opportunities for 2021 and Beyond. Cancers (Basel). 2021 May 21;13(11):2518. doi: 10.3390/cancers13112518.
- Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020 Jan;21(1):e18-e28. doi: 10.1016/S1470-2045(19)30718-1.
- Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020 Jul;148:157-166. doi: 10.1016/j.radonc.2020.04.003.
- Zilli T, Achard V, Dal Pra A, Schmidt-Hegemann N, Jereczek-Fossa BA, Lancia A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022 Nov;176:199-207. doi: 10.1016/j.radonc.2022.10.005.
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8-10. doi: 10.1200/JCO.1995.13.1.8.
- Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011 Jun;8(6):378-382. doi: 10.1038/nrclinonc.2011.44.
- Hong JC, Ayala-Peacock DN, Lee J, Blackstock AW, Okunieff P, Sung MW, et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018 Apr 12;13(4):e0195149. doi: 10.1371/journal.pone.0195149.
- Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020 Sep 1;38(25):2830-2838. doi: 10.1200/JCO.20.00818.
- Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860.
- Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947.
- Catton CN, Gospodarowicz MK. Palliative radiotherapy in prostate cancer. Semin Urol Oncol. 1997 Feb;15(1):65-72. PMID: 9050141.
- Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3.
- Rao A, Vapiwala N, Schaeffer EM, Ryan CJ. Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? Am Soc Clin Oncol Educ Book. 2019 Jan;39:309-320. doi: 10.1200/EDBK_239041.
- Onal C, Kose F, Ozyigit G, Aksoy S, Oymak E, Muallaoglu S, et al. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. Prostate. 2021 Jun;81(9):543-552. doi: 10.1002/pros.24132.
- Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049.
- Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002.
- Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, et al. Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol. 2014 Nov;66(5):799-802. doi: 10.1016/j.eururo.2014.05.038.
- Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298. doi: 10.6004/jnccn.2022.0063.
- Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020 Apr 11;395(10231):1208-1216. doi: 10.1016/S0140-6736(20)30314-7.
- Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3.
- Ali A, Hoyle A, Haran ÁM, Brawley CD, Cook A, Amos C, et al. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2021 Apr 1;7(4):555-563. doi: 10.1001/jamaoncol.2020.7857.
- Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ 3rd, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Netw Open. 2021 Jan 4;4(1):e2033787. doi: 10.1001/jamanetworkopen.2020.33787. Erratum in: JAMA Netw Open. 2021 Feb 1;4(2):e210615.
- Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008.
- Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al; STOPCAP M1 Radiotherapy Collaborators. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 2019 Jul;76(1):115-124. doi: 10.1016/j.eururo.2019.02.003.
- Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1095-1101. doi: 10.1016/s0360-3016(98)00438-6.
- Vogelius IR, Bentzen SM. Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865. doi: 10.1016/j.ijrobp.2017.12.011.
- Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1.
- Prospective randomized phase III trial of androgen deprivation therapy with or without docetaxel with or without local radiation therapy with or without abiraterone acetate and prednisolone in patients with metastatic hormone-naive prostate cancer (2021). Доступно по адресу: https://clinicaltrials.gov/ct2/show/NCT01957436/. Дата обращения: 28.03.2022.
- Singh K. Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial. Indian J Urol. 2022 Oct-Dec;38(4):323-324. doi: 10.4103/iju.iju_200_22. Epub 2022 Oct 1. PMID: 36568470; PMCID: PMC9787448.
- SWOG S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer. Доступно по адресу: https://www.swog.org/clinical-trials/s1802. Дата обращения: 29.03.2022.
- Reverberi C, Massaro M, Osti MF, Anzellini D, Marinelli L, Montalto A, et al. Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer. Sci Rep. 2020 Oct 15;10(1):17471. doi: 10.1038/s41598-020-74562-3.
- Deantoni CL, Fodor A, Cozzarini C, Fiorino C, Brombin C, Di Serio C, et al. Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases. Br J Radiol. 2020 Apr;93(1108):20190353. doi: 10.1259/bjr.20190353.
- Reyes DK, Rowe SP, Schaeffer EM, Allaf ME, Ross AE, Pavlovich CP, et al. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol. 2020 Jun 10;37(7):60. doi: 10.1007/s12032-020-01385-7.
- Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.
- Preisser F, Chun FK, Banek S, Wenzel M, Graefen M, Steuber T, et al. Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. Prostate Int. 2021 Sep;9(3):113-118. doi: 10.1016/j.prnil.2020.12.003.
- Canadian Cancer Research Group. A randomized phase III trial of local ablation therapy for hormone-sensitive oligometastatic prostate cancer [PLATON] (2022). Доступно по адресу: https://clinicaltrials.gov/ct2/show/NCT03784755. Дата обращения: 18.04.2022.
Статья научная
